Shanghai Mab-Venture Raises $35 Million in Funding Led by Prosperico Venture

Shanghai Mab-Venture Biopharma, a three-year old CRO/CMO, raised $35 million in a Series A round led by Prosperico Venture. The company focuses on biologics, including biosimilars, bio-betters and novel biologic drugs. It partners with other companies, both domestic and international, to provide development and manufacturing services, and it is developing it own portfolio of drugs. The company expects to file INDs in the next two to three years. Mab-Venture will use the funds to expand its innovative antibody drug development platforms and production capacity. More details.... Share this with colleagues: // //